These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 28421334)

  • 21. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
    Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Hann D; Marangell LB
    Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Working with reactant patients: are we prescribing nonadherence?
    Madsen JW; McQuaid JR; Craighead WE
    Depress Anxiety; 2009; 26(2):129-34. PubMed ID: 18972363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Receiving guideline-concordant pharmacotherapy for major depression: impact on ambulatory and inpatient health service use.
    Sewitch MJ; Blais R; Rahme E; Bexton B; Galarneau S
    Can J Psychiatry; 2007 Mar; 52(3):191-200. PubMed ID: 17479528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
    Mouchabac S; Ferreri M; Cabanac F; Bitton M
    Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Depressive symptoms during anorexia nervosa: State of the art and consequences for an appropriate use of antidepressants].
    Leblé N; Radon L; Rabot M; Godart N
    Encephale; 2017 Feb; 43(1):62-68. PubMed ID: 27452149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The metabolic syndrome and related characteristics in major depression: inpatients and outpatients compared: metabolic differences across treatment settings.
    Luppino FS; Bouvy PF; Giltay EJ; Penninx BW; Zitman FG
    Gen Hosp Psychiatry; 2014; 36(5):509-15. PubMed ID: 25001528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Duration of antidepressant drug treatment and its determinants in France].
    Tournier M; Cougnard A; Boutouaba-Combe S; Verdoux H
    Encephale; 2011 May; 37 Suppl 1():S36-41. PubMed ID: 21600331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
    Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Marangell LB
    Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode?
    Amsterdam JD; Shults J
    J Affect Disord; 2009 May; 115(1-2):234-40. PubMed ID: 18694599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study.
    Fava M; Ménard F; Davidsen CK; Baker RA
    J Clin Psychiatry; 2016 Dec; 77(12):1695-1701. PubMed ID: 27379823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Barriers and facilitators of adherence to antidepressants among outpatients with major depressive disorder: A qualitative study.
    Ho SC; Jacob SA; Tangiisuran B
    PLoS One; 2017; 12(6):e0179290. PubMed ID: 28614368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adherence to antidepressant treatment.
    Hansen HV; Kessing LV
    Expert Rev Neurother; 2007 Jan; 7(1):57-62. PubMed ID: 17187497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical features and drug induced side effects in early versus late antidepressant responders.
    Fabbri C; Marsano A; Balestri M; De Ronchi D; Serretti A
    J Psychiatr Res; 2013 Oct; 47(10):1309-18. PubMed ID: 23800418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
    Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
    Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Effect of a Drug Adherence Enhancement Program on the Drug Adherence Behaviors of Patients With Major Depressive Disorder in Thailand: A Randomized Clinical Trial.
    Vannachavee U; Seeherunwong A; Yuttatri P; Chulakadabba S
    Arch Psychiatr Nurs; 2016 Jun; 30(3):322-8. PubMed ID: 27256936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A case series on the use of lavendula oil capsules in patients suffering from major depressive disorder and symptoms of psychomotor agitation, insomnia and anxiety.
    Fißler M; Quante A
    Complement Ther Med; 2014 Feb; 22(1):63-9. PubMed ID: 24559818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy.
    Akiskal HS; Benazzi F; Perugi G; Rihmer Z
    J Affect Disord; 2005 Apr; 85(3):245-58. PubMed ID: 15780694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adherence to antidepressant therapy for major depressive patients in a psychiatric hospital in Thailand.
    Prukkanone B; Vos T; Burgess P; Chaiyakunapruk N; Bertram M
    BMC Psychiatry; 2010 Aug; 10():64. PubMed ID: 20727215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose desvenlafaxine in outpatients with major depressive disorder.
    Ferguson JM; Tourian KA; Rosas GR
    CNS Spectr; 2012 Sep; 17(3):121-30. PubMed ID: 22883315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.